Related Experiment Video
Updated: Jun 17, 2026
07:21
Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor
Published on: May 2, 2022
WT-1 expression in gastrointestinal stromal tumours.
Gu-Hyun Kang1, Kyoung-Mee Kim, Jae-Hyung Noh
1Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Pathology
|December 23, 2009
Summary
Wilms
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Wilms' tumour-1 (WT-1) is a transcription factor linked to tumour suppression.
- WT-1 overexpression is observed in various cancers, suggesting a broader role.
- Gastrointestinal stromal tumours (GISTs) are a significant group of mesenchymal neoplasms.
Purpose of the Study:
- To investigate Wilms' tumour-1 (WT-1) immunoreactivity in gastrointestinal stromal tumours (GISTs).
- To compare WT-1 expression with other GIST markers and clinicopathological features.
- To explore potential therapeutic implications of WT-1 in GIST.
Main Methods:
- Immunohistochemical analysis of WT-1 expression in 97 GIST samples.
- Comparison of WT-1 staining with platelet-derived growth factor receptor-alpha (PDGFRA) and other markers.
- Evaluation of WT-1 immunoreactivity in relation to clinicopathological variables and other tumour types.
Main Results:
- All 97 GISTs exhibited positive WT-1 immunoreactivity.
- Strong WT-1 staining was observed in 60.8% of GISTs.
- WT-1 expression did not correlate with clinicopathological features but showed association with PDGFRA positivity.
Conclusions:
- WT-1 is consistently expressed in GISTs, irrespective of clinicopathological characteristics.
- Findings suggest WT-1 as a potential target for GIST immunotherapy.
- This research may offer new therapeutic strategies for imatinib-resistant GIST.
